Disc Medicine Stock Performance
| IRON Stock | 92.60 2.25 2.49% |
On a scale of 0 to 100, Disc Medicine holds a performance score of 17. The firm shows a Beta (market volatility) of 0.8, which means possible diversification benefits within a given portfolio. As returns on the market increase, Disc Medicine's returns are expected to increase less than the market. However, during the bear market, the loss of holding Disc Medicine is expected to be smaller as well. Please check Disc Medicine's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Disc Medicine's price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Disc Medicine are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Disc Medicine displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.49 | Five Day Return 2.56 | Year To Date Return 48.28 | Ten Year Return (10.10) | All Time Return (10.10) |
Last Split Factor 1:30 | Last Split Date 2022-12-30 |
1 | Persistent Systems to Showcase Advanced Networking Solutions for Border Security at DSEI 2025 | 09/03/2025 |
2 | Acquisition by Quisel John D of 10000 shares of Disc Medicine at 1.01 subject to Rule 16b-3 | 09/09/2025 |
3 | Disc Medicine Evaluating Valuation Following FDA Application for Bitopertin in Erythropoietic Protoporphyria | 10/03/2025 |
4 | Disposition of 13267 shares by Bitterman Kevin of Disc Medicine at 72. subject to Rule 16b-3 | 10/08/2025 |
5 | Disposition of 2996 shares by Savage William Jacob of Disc Medicine at 50.0 subject to Rule 16b-3 | 10/17/2025 |
6 | Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones | 10/20/2025 |
7 | Disc Medicine Evaluating Valuation After New Clinical Trial Plans and FDA Recognition Boost Pipeline Momentum | 10/29/2025 |
8 | Disc Medicine stock reiterated Strong Buy at Raymond James on DISC-0974 potential - Investing.com | 10/31/2025 |
9 | Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis and Anemia at the 67th American Society of Hemat... | 11/03/2025 |
10 | Disc Medicine Expected to Announce Quarterly Earnings on Tuesday | 11/04/2025 |
11 | How Disc Medicines Clinical Data Updates and 250M Offering Have Reshaped Its Investment Story | 11/06/2025 |
12 | IRONS Founder Inducted into Idaho Technology Council Hall of Fame | 11/07/2025 |
13 | Cerrado Gold Provides Update on Its Mont Sorcier High Grade Direct Reduction Iron Project in Quebec | 11/10/2025 |
14 | Will Disc Medicine Inc. stock recover faster than market - 2025 Support Resistance Technical Confirmation Trade Alerts - newser.com | 11/13/2025 |
15 | Jefferies reiterates Buy rating on Disc Medicine stock ahead of key catalysts - Investing.com | 11/20/2025 |
| Begin Period Cash Flow | 360.6 M | |
| Total Cashflows From Investing Activities | -292.3 M |
Disc Medicine Relative Risk vs. Return Landscape
If you would invest 5,941 in Disc Medicine on August 24, 2025 and sell it today you would earn a total of 3,319 from holding Disc Medicine or generate 55.87% return on investment over 90 days. Disc Medicine is currently generating 0.7462% in daily expected returns and assumes 3.3202% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Disc, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Disc Medicine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Disc Medicine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Disc Medicine, and traders can use it to determine the average amount a Disc Medicine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2247
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IRON | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.32 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.75 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Disc Medicine is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Disc Medicine by adding it to a well-diversified portfolio.
Disc Medicine Fundamentals Growth
Disc Stock prices reflect investors' perceptions of the future prospects and financial health of Disc Medicine, and Disc Medicine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Disc Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 2.83 B | ||||
| Shares Outstanding | 37.75 M | ||||
| Price To Book | 5.95 X | ||||
| EBITDA | (108.27 M) | ||||
| Net Income | (109.36 M) | ||||
| Total Debt | 30 M | ||||
| Book Value Per Share | 16.38 X | ||||
| Cash Flow From Operations | (93.93 M) | ||||
| Earnings Per Share | (5.37) X | ||||
| Market Capitalization | 3.5 B | ||||
| Total Asset | 496.77 M | ||||
| Retained Earnings | (298 M) | ||||
| Working Capital | 470.3 M | ||||
About Disc Medicine Performance
By examining Disc Medicine's fundamental ratios, stakeholders can obtain critical insights into Disc Medicine's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Disc Medicine is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.27) | (0.26) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.25) | (0.23) |
Things to note about Disc Medicine performance evaluation
Checking the ongoing alerts about Disc Medicine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Disc Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Disc Medicine appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (109.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Disc Medicine generates negative cash flow from operations | |
| Disc Medicine has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Jefferies reiterates Buy rating on Disc Medicine stock ahead of key catalysts - Investing.com |
- Analyzing Disc Medicine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Disc Medicine's stock is overvalued or undervalued compared to its peers.
- Examining Disc Medicine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Disc Medicine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Disc Medicine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Disc Medicine's stock. These opinions can provide insight into Disc Medicine's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.